📰 Botensilimab/balstilimab produced an estimated 3-year OS rate of 48% in heavily pretreated recurrent ovarian cancer in the ovarian cohort of the phase 1b C-800-01 trial. @danafarber.bsky.social #IGCS2026 #gyncsm #oncology
Read more ➡️: www.onclive.com/view/botensi...
